Fludarabine phosphate for the treatment of low grade lymphoid malignancy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108390
Title:
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Authors:
Whelan, J S; Davis, C L; Rule, S; Ranson, Malcolm R; Smith, O P; Mehta, A B; Catovsky, D; Rohatiner, A Z; Lister, T A
Abstract:
Thirty-four patients with previously treated, advanced, low grade NHL were treated with Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 intravenously, daily for 5 days (median number of cycles = 3, range 1-10). Complete remission (CR) was achieved in six and partial remission (PR) in a further seven. Overall, responses were seen in 11/23 patients (48%) with follicular lymphoma and in 2/11 (18%) with low grade, diffuse NHL. Fifteen patients with previously treated CLL and one patient with prolymphocytic leukaemia (PLL) were also treated as above (median no. of cycles = 3, range 1-6). A partial response was seen in three of the 11 evaluable patients with CLL and CR was achieved in the patient with PLL. There were four deaths due to infection and 19 further episodes requiring admission to hospital. No other significant toxicity was reported in a total of 164 cycles of Fludarabine. This agent is active in advanced low grade lymphoid malignancy. Further studies are required to assess its role in newly diagnosed patients.
Affiliation:
ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Citation:
Fludarabine phosphate for the treatment of low grade lymphoid malignancy. 1991, 64 (1):120-3 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jul-1991
URI:
http://hdl.handle.net/10541/108390
PubMed ID:
1713049
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWhelan, J Sen
dc.contributor.authorDavis, C Len
dc.contributor.authorRule, Sen
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorSmith, O Pen
dc.contributor.authorMehta, A Ben
dc.contributor.authorCatovsky, Den
dc.contributor.authorRohatiner, A Zen
dc.contributor.authorLister, T Aen
dc.date.accessioned2010-07-27T10:55:28Z-
dc.date.available2010-07-27T10:55:28Z-
dc.date.issued1991-07-
dc.identifier.citationFludarabine phosphate for the treatment of low grade lymphoid malignancy. 1991, 64 (1):120-3 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid1713049-
dc.identifier.urihttp://hdl.handle.net/10541/108390-
dc.description.abstractThirty-four patients with previously treated, advanced, low grade NHL were treated with Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 intravenously, daily for 5 days (median number of cycles = 3, range 1-10). Complete remission (CR) was achieved in six and partial remission (PR) in a further seven. Overall, responses were seen in 11/23 patients (48%) with follicular lymphoma and in 2/11 (18%) with low grade, diffuse NHL. Fifteen patients with previously treated CLL and one patient with prolymphocytic leukaemia (PLL) were also treated as above (median no. of cycles = 3, range 1-6). A partial response was seen in three of the 11 evaluable patients with CLL and CR was achieved in the patient with PLL. There were four deaths due to infection and 19 further episodes requiring admission to hospital. No other significant toxicity was reported in a total of 164 cycles of Fludarabine. This agent is active in advanced low grade lymphoid malignancy. Further studies are required to assess its role in newly diagnosed patients.en
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshVidarabine-
dc.subject.meshVidarabine Phosphate-
dc.titleFludarabine phosphate for the treatment of low grade lymphoid malignancy.en
dc.typeArticleen
dc.contributor.departmentICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.